The historical data trend for Moderna's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MRNA vs RPRX, ROIV, ONC: Buyback Yield % Comparison
For the Biotechnology subindustry, Moderna's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moderna's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Moderna's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna (XSWX:MRNA) has a Buyback Yield % of -0.18 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Moderna and its competitors. According to the industry distribution chart, Moderna ranks #154 out of 745 companies in the Biotechnology industry, placing it in the top 20.7%.
Is Moderna's Buyback Yield % too high?
Moderna's current Buyback Yield % is -0.18. Based on the distribution chart, Moderna ranks #154 out of 745 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Moderna has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Moderna's Buyback Yield % compare to RPRX and ROIV?
According to the Biotechnology industry distribution chart, Moderna ranks #154 out of 745 companies for Buyback Yield %. This places Moderna in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Moderna and its competitors. Moderna's current Buyback Yield % is -0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Moderna (XSWX:MRNA) has a current Buyback Yield % of -0.18. The stock's GF Value™ is CHF18.28, compared to a current price of CHF58.54 — trading 220.2% above its estimated fair value. The current Buyback Yield % is -0.18. Moderna's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Moderna (XSWX:MRNA), the current Buyback Yield % is -0.18 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moderna (XSWX:MRNA) Overvalued in 2026?
Based on GuruFocus' analysis, Moderna stock appears to be overvalued.
The current stock price of CHF58.54 is trading 220.2% above its estimated GF Value™ of CHF18.28.
Key valuation signals for XSWX:MRNA:
Buyback Yield %: -0.18
GF Value™: CHF18.28 vs. price of CHF58.54 (220.2% above fair value)
No single metric tells the full story. See the XSWX:MRNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
62GF Score
Get the complete analysis for XSWX:MRNA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MRNA has been successfully added to your 
